UC San Diego Adaptamers Control Gene Therapy Protein Output

Preclinical research shows drug-activated FGF21 production can drive weight loss and reverse liver fat in laboratory experiments.

Updated on Nov. 17, 2026 in Health

UC San Diego Adaptamers Control Gene Therapy Protein Output

Bioengineers at the University of California San Diego developed adaptamers, short RNA molecules that use small-molecule drugs to regulate how much protein cells produce from gene therapy. In preclinical studies, activating FGF21 production with the technology caused substantial weight loss and almost completely reversed fat accumulation in the liver.

Why it matters

Cells can keep producing a therapeutic protein long after genetic instructions are delivered, which can cause unwanted side effects. Because stopping the activating drug lets protein production fall without removing the gene therapy, the approach offers a way to switch treatment output on and off.

The results come from preclinical experiments that measured weight, blood sugar and liver fat after FGF21 production was activated with tetracycline or doxycycline, but the extraction does not provide specific effect sizes. Human safety and effectiveness have not been tested, and the researchers say more work is needed.

The players

University of California San Diego

A public research university in San Diego, California, whose bioengineering researchers developed the adaptamer technology.

Prashant Mali

A professor of bioengineering at the University of California San Diego who leads the laboratory where the adaptamer technology was developed.

The details

Adaptamers bind small-molecule drugs and, when activated, trigger a natural cellular process that lets cells read genetic instructions and produce the desired protein. The team engineered the system to control fibroblast growth factor 21 (FGF21), and the researchers note that excessive or prolonged FGF21 exposure can contribute to muscle loss and reduced bone density.

Timeline

  1. Preclinical experiments were reported on 2026-11-17 without a specified study date.

Health Landscape

Gene therapies have been constrained by the difficulty of turning protein output down once genetic instructions are delivered, and the adaptamer approach offers a drug-switchable alternative to that permanent expression. The work remains preclinical and has not yet been shown to be safe or effective in people.

For now the adaptamer approach is confined to laboratory research, so it does not change current treatment options or daily health routines for patients. Any future application would first need human safety and effectiveness testing before affecting access or costs.

The takeaway

Researchers are testing a way to turn gene therapy protein output up or down with a drug, which could one day reduce the risk of side effects from therapies that keep producing proteins indefinitely. Readers should treat the results as early laboratory findings rather than a proven treatment.

Further reading

Explore more Weight Loss coverage from San Diego, where the adaptamer research was conducted.

Source note: This article includes information reported by Drug Target Review.